|
|
|||||||
 |
|
|
LinkBack | Thread Tools | Display Modes |
04-20-2010, 11:15 PM
|
|||
|
|||
NewLink Genetics Presents Positive Phase1/2 Data On HyperAcute(R)-Lung Cancer Immunot
NewLink Genetics Corporation announced data from a Phase 1/2 study showing that patients with progressive advanced non-small cell lung cancer treated with its HyperAcute-Lung cancer immunotherapy experienced favorable median survival. The data were presented at the 101st American Association for Cancer Research (AACR) Annual Meeting...
    
|
|
| Thread Tools | |
| Display Modes | |
|
|
Similar Threads
|
||||
| Thread | Thread Starter | Forum | Replies | Last Post |
| NewLink Genetics reports positive data from Phase 2 trial of HyperAcute-Pancreas canc | cancerfr | Pancreatic Cancer | 0 | 06-07-2010 07:43 PM |
| NewLink Genetics to present Phase 2 data of HyperAcute-Pancreas immunotherapy for res | cancerfr | Pancreatic Cancer | 0 | 05-20-2010 06:16 PM |
| Positive data from NewLink Genetics Phase1/2 study of HyperAcute-Lung cancer immunoth | cancerfr | Oral Cancer | 0 | 04-20-2010 11:15 PM |
| Data On NewLink Genetics' HyperAcute(R) Lung Cancer Immunotherapy To Be Presented At | cancerfr | Lung Cancer | 0 | 04-16-2010 08:46 PM |
| Data on NewLink Genetics' HyperAcute(R) Lung Cancer Immunotherapy to be Presented at | cancerfr | Lung Cancer | 0 | 04-16-2010 04:39 AM |
Linear Mode
